Gufic Biosciences Limited (GUFICBIO.BO)
INR 449.05
(0.28%)
INR 449.05
(0.28%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.16 Billion INR | -19.14% |
| 2022 | 3.58 Billion INR | -2.29% |
| 2021 | 3.67 Billion INR | 59.7% |
| 2020 | 2.29 Billion INR | 19.84% |
| 2019 | 1.91 Billion INR | 13.56% |
| 2018 | 1.68 Billion INR | 5.4% |
| 2017 | 1.6 Billion INR | 31.01% |
| 2016 | 1.22 Billion INR | 25.19% |
| 2015 | 977.3 Million INR | 42.01% |
| 2014 | 688.18 Million INR | 23.91% |
| 2013 | 555.39 Million INR | 15.26% |
| 2012 | 481.84 Million INR | 27.66% |
| 2011 | 377.45 Million INR | 9.33% |
| 2010 | 345.24 Million INR | 19.73% |
| 2009 | 288.36 Million INR | 22.31% |
| 2008 | 235.76 Million INR | 14.39% |
| 2007 | 206.1 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 747.21 Million INR | 4.22% |
| 2023 Q3 | 1.06 Billion INR | 0.64% |
| 2023 Q4 | 716.97 Million INR | -32.64% |
| 2023 FY | 2.9 Billion INR | -19.14% |
| 2023 Q2 | 1.05 Billion INR | 7.73% |
| 2023 Q1 | 981.8 Million INR | 8.52% |
| 2022 FY | 3.58 Billion INR | -2.29% |
| 2022 Q3 | 911.32 Million INR | 1.88% |
| 2022 Q4 | 904.72 Million INR | -0.72% |
| 2022 Q1 | 877.44 Million INR | 20.12% |
| 2022 Q2 | 894.5 Million INR | 1.94% |
| 2021 Q3 | 842.13 Million INR | -5.67% |
| 2021 Q4 | 730.48 Million INR | -13.26% |
| 2021 Q1 | 1.02 Billion INR | 19.73% |
| 2021 FY | 3.67 Billion INR | 59.7% |
| 2021 Q2 | 892.77 Million INR | -13.31% |
| 2020 FY | 2.29 Billion INR | 19.84% |
| 2020 Q4 | 860.14 Million INR | 18.0% |
| 2020 Q3 | 728.94 Million INR | 10.11% |
| 2020 Q2 | 662 Million INR | 108.41% |
| 2020 Q1 | 317.64 Million INR | -16.75% |
| 2019 Q4 | 381.56 Million INR | -23.31% |
| 2019 Q3 | 497.5 Million INR | 23.8% |
| 2019 Q2 | 401.85 Million INR | -18.2% |
| 2019 Q1 | 491.26 Million INR | 6.15% |
| 2019 FY | 1.91 Billion INR | 13.56% |
| 2018 Q3 | 432.4 Million INR | 8.88% |
| 2018 FY | 1.68 Billion INR | 5.4% |
| 2018 Q4 | 462.79 Million INR | 7.03% |
| 2018 Q2 | 397.15 Million INR | -15.43% |
| 2018 Q1 | 469.63 Million INR | 11.93% |
| 2017 Q1 | 316.31 Million INR | 7.7% |
| 2017 FY | 1.6 Billion INR | 31.01% |
| 2017 Q3 | 450.12 Million INR | 16.65% |
| 2017 Q4 | 419.55 Million INR | -6.79% |
| 2017 Q2 | 385.87 Million INR | 21.99% |
| 2016 FY | 1.22 Billion INR | 25.19% |
| 2016 Q2 | 313.13 Million INR | 6.41% |
| 2016 Q1 | 294.26 Million INR | 20.42% |
| 2016 Q4 | 293.7 Million INR | -13.61% |
| 2016 Q3 | 339.97 Million INR | 8.57% |
| 2015 Q1 | 212.65 Million INR | 30.02% |
| 2015 Q2 | 252.05 Million INR | 18.53% |
| 2015 Q3 | 268.23 Million INR | 6.42% |
| 2015 FY | 977.3 Million INR | 42.01% |
| 2015 Q4 | 244.35 Million INR | -8.9% |
| 2014 Q3 | 174.41 Million INR | -1.88% |
| 2014 Q4 | 163.56 Million INR | -6.22% |
| 2014 Q2 | 177.75 Million INR | 3.99% |
| 2014 Q1 | 170.93 Million INR | 18.93% |
| 2014 FY | 688.18 Million INR | 23.91% |
| 2013 Q2 | 118.5 Million INR | -1.87% |
| 2013 Q4 | 143.72 Million INR | -16.64% |
| 2013 FY | 555.39 Million INR | 15.26% |
| 2013 Q3 | 172.4 Million INR | 45.48% |
| 2013 Q1 | 120.76 Million INR | 12.89% |
| 2012 FY | 481.84 Million INR | 27.66% |
| 2012 Q1 | 115.15 Million INR | 3.29% |
| 2012 Q4 | 106.97 Million INR | -10.73% |
| 2012 Q3 | 119.82 Million INR | -14.34% |
| 2012 Q2 | 139.88 Million INR | 21.47% |
| 2011 Q3 | 92.46 Million INR | 0.0% |
| 2011 FY | 377.45 Million INR | 9.33% |
| 2011 Q4 | 111.48 Million INR | 20.57% |
| 2010 FY | 345.24 Million INR | 19.73% |
| 2009 FY | 288.36 Million INR | 22.31% |
| 2008 FY | 235.76 Million INR | 14.39% |
| 2007 FY | 206.1 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ajanta Pharma Limited | 21.06 Billion INR | 80.214% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -167.756% |
| Sigachi Industries Limited | 2 Billion INR | -108.148% |
| Bal Pharma Limited | 770.19 Million INR | -441.123% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 32.718% |
| Medico Remedies Limited | 262.14 Million INR | -1489.853% |
| Lasa Supergenerics Limited | 121.02 Million INR | -3343.531% |
| Venus Remedies Limited | 2.18 Billion INR | -90.953% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 791.843% |
| Alpa Laboratories Limited | 188.89 Million INR | -2106.361% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -40.23% |
| Shilpa Medicare Limited | 3.54 Billion INR | -17.504% |
| Aarti Drugs Limited | 8.31 Billion INR | 49.885% |
| Lupin Limited | 123.71 Billion INR | 96.631% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 97.306% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 96.671% |
| Windlas Biotech Limited | 1.33 Billion INR | -211.302% |
| Suven Life Sciences Limited | -200.79 Million INR | 2175.581% |
| Eris Lifesciences Limited | 10.42 Billion INR | 60.029% |
| Valiant Laboratories Limited | -60.66 Million INR | 6970.145% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 81.64% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -383.942% |
| Ipca Laboratories Limited | 29.8 Billion INR | 86.019% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -12.78% |
| Achyut Healthcare Limited | 4.86 Million INR | -85637.605% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 98.388% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -183.169% |
| RPG Life Sciences Limited | 2.48 Billion INR | -67.85% |
| Mankind Pharma Limited | 44.52 Billion INR | 90.639% |
| Laurus Labs Limited | 24.62 Billion INR | 83.072% |
| Piramal Pharma Limited | 24.47 Billion INR | 82.969% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -342.244% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 91.087% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 84.438% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 93.99% |
| Unichem Laboratories Limited | 4.86 Billion INR | 14.332% |
| Sequent Scientific Limited | 2.97 Billion INR | -39.916% |
| Novartis India Limited | 1.32 Billion INR | -214.093% |
| Wanbury Limited | 1.73 Billion INR | -140.818% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -1.078% |
| Wockhardt Limited | 16.24 Billion INR | 74.337% |
| Themis Medicare Limited | 1.5 Billion INR | -177.126% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -538.641% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 78.783% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 66.479% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 97.453% |
| Divi's Laboratories Limited | 32.44 Billion INR | 87.153% |
| NATCO Pharma Limited | 25.73 Billion INR | 83.806% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 9.018% |
| Ind-Swift Limited | 2.17 Billion INR | -91.836% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 27.912% |
| FDC Limited | 8.33 Billion INR | 49.996% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -2062.492% |
| Granules India Limited | 16.79 Billion INR | 75.191% |
| Medicamen Biotech Limited | 495.49 Million INR | -741.119% |
| Alkem Laboratories Limited | 52.29 Billion INR | 92.031% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 33.024% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -28485.67% |
| Brooks Laboratories Limited | 65.62 Million INR | -6251.272% |
| Megasoft Limited | 342.07 Million INR | -1118.374% |
| ZIM Laboratories Limited | 1.26 Billion INR | -228.972% |
| Strides Pharma Science Limited | 14.38 Billion INR | 71.034% |
| Neuland Laboratories Limited | 8.24 Billion INR | 49.469% |
| Morepen Laboratories Limited | 6.16 Billion INR | 32.357% |
| Hikal Limited | 3.14 Billion INR | -32.599% |
| Indoco Remedies Limited | 6.04 Billion INR | 31.013% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 28.529% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -571.694% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -492.336% |
| Hester Biosciences Limited | 1.27 Billion INR | -227.225% |